Cubist Pharmaceuticals Inc., of Lexington, Mass., reported second quarter net U.S. sales of $168.6 million for antibiotic Cubicin (daptomycin), while the firm's net product revenues from international sales were $7.7 million. The company reported total net revenue of $176.8 million, up 9 percent over the same quarter in 2010. Net loss was $20.6 million, or 34 cents per share, far below consensus estimates, which had predicted net income earnings per share of 41 cents.